Tablet sales strong at ALK Abello in the second quarter

13 August 2019

Positive growth from tablet products propelled allergy immunotherapy specialist ALK Abello (ALKB: DC) to a strong performance in the second quarter of 2019, with total revenues up 9% at 785 million Danish kroner ($117 million).

The firm said it benefited from operational efficiencies as well as higher revenues to deliver an operating profit of 24 million Danish kroner, before interest, tax, depreciation and amortization (EBITDA).

Record revenue figures for the second quarter, part of the low season for allergies, were backed up by 42% growth from tablets, and growth in all regions, including 7% in Europe and 42% in other markets globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK